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ABSTRACT 
Preclinical studies have demonstrated synergy between poly(ADP-ribose) 
polymerase (PARP) and phosphatidylinositol-3-kinase (PI3K)/AKT pathway inhibitors 
in BRCA1 and BRCA2 (BRCA1/2)-deficient and BRCA1/2-proficient tumors. We 
conducted an investigator-initiated phase I trial utilizing a prospective intrapatient 
dose-escalation design to assess two schedules of capivasertib (AKT inhibitor) with 
olaparib (PARP inhibitor) in 64 patients with advanced solid tumors. Dose 
expansions enrolled germline BRCA1/2-mutant tumors, or BRCA1/2-wildtype 
cancers harboring somatic DNA damage response (DDR) or PI3K/AKT pathway 
alterations. The combination was well-tolerated. Recommended phase 2 doses for 
the two schedules were: olaparib 300mg BID with either capivasertib 400mg BID 4-
days-on, 3-days-off, or capivasertib 640mg BID 2-days-on, 5-days-off. 
Pharmacokinetics were dose-proportional. Pharmacodynamic studies confirmed 
pGSK3β suppression, increased pERK and decreased BRCA1 expression. 25 
(44.6%) of 56 evaluable patients achieved clinical benefit (RECIST CR/PR or stable 
disease ≥4 months), including patients with tumors harboring germline BRCA1/2-
mutations and BRCA1/2-wildtype cancers with or without DDR and PI3K/AKT 
pathway alterations.  
 
Running title: Phase I trial of olaparib and capivasertib in solid tumors 
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STATEMENT OF SIGNIFICANCE 
In the first trial to combine poly(ADP-ribose) polymerase and AKT inhibitors, a 
prospective intrapatient dose-escalation design demonstrated safety, tolerability, 
pharmacokinetic-pharmacodynamic activity, and assessed predictive biomarkers of 
response/resistance. Antitumor activity was observed in patients harboring tumors 
with germline BRCA1/2-mutations and BRCA1/2-wildtype cancers with or without 
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INTRODUCTION 
Poly(ADP-ribose) polymerase (PARP) inhibitors are the first clinically 
approved drugs designed to exploit synthetic lethality in homologous recombination 
(HR) deficient cells, demonstrating proof of concept activity in BRCA1/2 mutant 
cancers (1,2). The PARP inhibitor olaparib (Lynparza, AstraZeneca) was the first-in-
class to be approved by the Food and Drug Administration (FDA) in the advanced 
recurrent ovarian cancer setting for women with BRCA1/2 mutant cancers (3). 
Olaparib has subsequently received FDA approval in the maintenance setting for 
recurrent platinum-sensitive ovarian cancers regardless of BRCA1/2 status and most 
recently in the first-line maintenance setting post-platinum-based chemotherapy both 
in women with germline or somatic BRCA1/2 mutated advanced ovarian cancer and 
in patients with germline BRCA1/2 mutated pancreatic cancer (4,5). Olaparib is also 
FDA approved for the treatment of patients with germline BRCA1/2 mutant, HER2-
negative metastatic breast cancers (6,7). In addition, there are now early clinical trial 
data in patients with tumors harboring other DNA repair aberrations (8). 
 
Despite these broader indications, the greatest clinical benefit from PARP 
inhibitor monotherapy has been observed in the high grade serous germline 
BRCA1/2 mutant ovarian cancer population (3). However, these patients almost 
inevitably develop PARP inhibitor resistance and disease progression. The utility of 
PARP inhibitor monotherapy in patients with different cancers harboring other DNA 
repair aberrations is also limited by the emergence of drug resistance and generally 
shortlived antitumor responses (9). Even for patients with advanced solid tumors 
bearing deleterious BRCA1/2 mutations, response rates are between 30-60% 
depending on tumor type (3). There is therefore a major unmet need for novel 
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antitumor strategies to increase both the proportion of patients with clinical benefit, 
as well as the depth and duration of response for patients treated with PARP 
inhibitors (10). Such approaches include the development of rational combination 
strategies. Multiple preclinical studies have demonstrated synergistic antitumor 
activity with the combination of PARP and phosphatidylinositol-3-kinase (PI3K)/AKT 
pathway inhibitors in both BRCA-deficient and proficient cancer models (11-14). PI3K 
pathway inhibition has been shown to lead to suppression of BRCA gene 
transcription, which was accompanied by extracellular signal-regulated kinase (ERK) 
phosphorylation. Overexpression of an active form of MEK1 was found to result in 
ERK activation and downregulation of BRCA1, resulting in HR deficiency and 
subsequent PARP inhibitor sensitivity, thus providing strong rationale for the 
development of this combination as an antitumor strategy (11). A phase Ib trial of 
olaparib in combination with the -specific PI3K inhibitor alpelisib demonstrated 
RECIST partial responses in 10 (36%) of 28 patients with ovarian cancer, providing 
early clinical proof-of-concept (15). 
 
Several novel molecularly targeted agents against the PI3K-AKT pathway 
have now been developed, including the AKT inhibitor capivasertib (AZD5363; 
AstraZeneca) (16). Capivasertib is a potent and selective ATP competitive inhibitor 
of all 3 isoforms of AKT, which is safe and well tolerated in patients with advanced 
solid tumors, but with limited antitumor benefit as a single agent in early phase 
clinical trials (17-19). This is hypothesized to be due to multiple factors, including the 
development of signaling crosstalk and disruption of feedback loops, leading to 
acquired resistance, supporting the use of combination strategies in molecularly 
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defined patients for the optimal development of AKT inhibitors, such as with PARP 
inhibitors as described above (20,21).  
 
Based on these promising data, we conducted an investigator-initiated phase 
Ib clinical trial to determine the safety, tolerability, maximum tolerated dose (MTD), 
recommended phase 2 dose (RP2D), pharmacokinetics (PK), pharmacodynamics 
(PD) and preliminary antitumor activity of olaparib in combination with capivasertib in 
patients with advanced solid tumors. We also assessed a prospective intrapatient 
dose escalation strategy where patients were permitted to prospectively increase 
doses of capivasertib after each cycle (if no Grade (G) 2 or worse toxicities were 
observed) in combination with a fixed olaparib dose. RP2D expansion cohorts were 
undertaken in patients with (1) germline BRCA1/2 mutant cancers and (2) sporadic 
cancers with DNA damage response (DDR) aberrations or molecular abnormalities 
along the PI3K-AKT pathway. Detailed analyses of archived and fresh sequential 
tumor biopsies, as well as targeted sequencing of serial cell-free DNA (cfDNA) 
samples were conducted to identify determinants of response and resistance, 
including genomic factors and protein expression, and pharmacodynamic 




 We enrolled 64 patients with advanced solid tumors from four major cancer 
centres in the United Kingdom into the dose escalation (20 patients) or expansion 
(44 patients) cohorts of this phase I trial. Characteristics of these patients are 
provided in Table 1. The most common tumor enrolled was advanced ovarian 
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cancer (39% of patients); these patients received a median of 5 prior therapies 
(range 1-12). The next most common tumor type was advanced breast cancer (28% 
of patients); these paitents received a median number of 3 prior therapies (range 2-
10). 
 
Prospective intrapatient dose escalation 
The prospective intrapatient dose escalation strategy utilized during each 
dose schedule allowed rapid, seamless and safe dose escalation, resulting in 
completion of the dose escalation phases of two combination schedules over 3 dose 
levels in 7 months (Supplementary Figure 1). Overall, only 10 patients were 




During the dose escalation phase of the 4-days-on, 3-days-off (4/3) schedule, 
doses of capivasertib were increased using the prospective intrapatient dose 
escalation design from 320mg, 400mg to 480mg BID with a fixed dose of olaparib at 
300mg BID (Supplementary Figure 1). Of 10 patients treated in this 4/3 schedule, 
only 1 DLT of G3 maculopapular rash, typical of that observed with capivasertib and 
other AKT inhibitors, was observed at the highest dose assessed of capivasertib 
480mg BID with olaparib 300mg BID (Table 2). The erythematous rash fully resolved 
after both capivasertib and olaparib were withheld, and no recurrent rash was 
observed after both drugs were restarted at a reduced dose of capivasertib 400mg 
BID with olaparib maintained at 300mg BID. At the dose level of capivasertib 480mg 
BID with olaparib 300mg BID administered in a 4/3 schedule, other non-DLT G3 
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toxicities were observed, including anemia (n=1), vomiting (n=1) and diarrhea (n=2). 
Due to the DLT of G3 rash, non-DLT G3 AEs and chronic low grade adverse events, 
e.g. fatigue and anemia, observed outside the DLT period of 21 days at the dose of 
capivasertib 480mg BID with olaparib 300mg BID, the SRC established the dose 
level of olaparib 300mg BID with capivasertib 400mg BID as the RP2D for the 4/3 
schedule. 
 
For the 2-days-on, 5-days-off (2/5) schedule of capivasertib with olaparib 
300mg BID, dose escalation proceeded through dose levels of 480mg, 560mg and 
640mg BID with olaparib 300mg BID. In the 10 patients treated on the 2/5 schedule, 
no DLTs were observed for the 2/5 schedule, and the highest dose level of 
capivasertib at 640mg BID with olaparib 300mg BID was selected as the RP2D. In 
view of similarities in overall safety, tolerability and DLT rates, the SRC elected to 
explore both the 4/3 and 2/5 schedules of capivasertib in the dose expansion phase. 
 
The most common all grade treatment-emergent adverse events (TEAE) 
observed for all patients across both dose schedules were gastrointestinal toxicities, 
including nausea (67%, [grade 3-4, 4%]), diarrhea (55%, [grade 3-4, 6%]) and 
vomiting (41%, [grade 3-4, 5%]), as well as fatigue (51%, [grade 3-4, 5%]) (Table 2; 
Supplementary Tables 1 and 2). Other significant grade 3-4 toxicities included 
grade 3 anemia (10%) on the 4/3 schedule. Overall, the 4/3 schedule appeared to be 
less well tolerated than the 2/5 schedule, as exhibited during dose escalation: six 
grade 3 TEAEs (anemia and diarrhea [n=2 each]; rash and vomiting [n=1 each]) 
were observed with the 4/3 schedule, and only three grade 3 TEAEs (liver 
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transaminitis, fatigue and hyperglycemia [all n=1]) in the 2/5 schedule. No drug-
related grade 4-5 toxicities were observed in either schedule. 
 
Pharmacokinetics 
Dose escalation of capivasertib showed dose dependent increases in PK 
exposures (Figures 1A and 1B; Supplementary Tables 3 and 4). The PK profile 
and overall concentration-time profile of capivasertib and olaparib were similar to that 
previously observed in single agent studies, with no significant interactions identified. 
 
Pharmacodynamics 
PD studies in platelet-rich plasma (PRP) showed significant decrease in Ser9 
GSK3 phosphorylation post-treatment at all doses in the escalation and expansion 
(Figures 2A and 2B), confirming target modulation by capivasertib. Phosphorylated 
ERK expression levels assessed with IHC increased in fresh tumor biopsies 
collected on cycle 1 day 15 compared with baseline samples in six of 8 patients, 
while remaining unchanged in 1 patient and decreasing in another patient (Figure 
2C). At the same time point, BRCA1 expression decreased in paired fresh tumor 
biopsies obtained from all 8 patients (Figure 2D). 
 
Antitumor activity 
The antitumor activity of the combination of capivasertib and olaparib is 
detailed in Table 3, Figures 3A-3C, and Supplementary Table 5. Of the 56 
patients who were evaluable for antitumor response, nineteen (34%) patients had 
RECIST PRs and/or tumor marker response (GCIG (Gynaecologic Cancer 
InterGroup) CA-125 response or Prostate Cancer Clinical Trials Working Group 2 
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(PCWG2) PSA response). Fourteen (25%) patients achieved RECIST PRs (12 
confirmed and 2 unconfirmed). In addition, eleven (20%) patients had RECIST stable 
disease for at least 4 months (SD≥4 months), giving a clinical benefit rate (CBR) of 
44.6% (95% CI: 31.3, 58.5). Of these 56 evaluable patients, sixteen (29%) patients 
were treated on study for more than 6 months, while seven (13%) patients were 
treated on trial for more than 1 year.  
 
Molecular characteristics of patients with clinical benefit 
Among the 25 (44.6%) patients who achieved clinical benefit (RECIST CR/PR 
or SD≥4 months), 14 (56%) patients had germline BRCA1 or BRCA2 mutations 
(ovarian cancer (n=7), breast cancer (n=5) and castration-resistant prostate cancer 
(CRPC; n=2)) (Table 3; Figures 3A-3C; Supplementary Table 5). Seven of the 
remaining patients had pathogenic DDR or PI3K pathway aberrations detected, while 
three patients did not, and one patient did not have available tissue for NGS testing. 
 
Antitumor responses in patients with DDR and/or PI3K pathway mutations 
 Three RECIST-evaluable patients harboring tumors with both DDR-related 
and PI3K pathway mutations achieved RECIST PRs (Figure 3B). The mutations for 
these 3 patients were: (1) germline ERCC2 mutation, somatic PIK3CA and PTEN 
mutations and PTEN IHC loss; (2) somatic BRCA2 mutation and PTEN IHC loss; 
and (3) germline BRCA2 and PIK3CA mutations, respectively. Eight of 22 (36.4%) 
patients with tumors harboring only DDR-related mutations achieved RECIST PR, 
including those with BRCA1 (n=5), BRCA2 (n=2) and PALB2 (n=1) mutations. A 
further eight patients had a best response of SD≥4 months. Among those patients 
with tumors harboring only PI3K pathway mutations (n = 5), there was one objective 
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response in a patient with a tumor found to have a PTEN mutation. In patients with 
tumors harboring neither PI3K pathway nor DDR-related mutations (n=25), there 
were two RECIST PRs.  
 
Patients with BRCA1/2 mutant cancers 
Among 25 patients with BRCA1/2 mutant cancers (20 with germline BRCA1/2 
mutations, 5 with somatic BRCA1/2 mutations; breast (n=7), ovarian (n=15) and 
CRPC (n=3)), 22 patients had RECIST-measurable disease; 16 (72%) of these 22 
patients achieved clinical benefit with the combination of olaparib and capivasertib. 
 
Patients with advanced breast cancer 
A total of 18 patients with advanced breast cancer were enrolled onto the 
study, 8 (44%) of whom achieved clinical benefit (Supplementary Table 5). Five 
(71.4%) out of 7 patients with BRCA1/2 mutant breast cancer had clinical benefit; 
four had RECIST PR and one had SD of 19.4 weeks, with a median duration of 
response of 39.1 weeks (range: 14.9 – 80.9). Two of these responders with clinical 
benefit were platinum-resistant. None of the responding patients with advanced 
breast cancer had prior therapy with PARP or PI3K pathway inhibitors. 
 
Patients with advanced ovarian cancer 
There were a total of 25 patients with advanced ovarian cancer, 11 of whom 
achieved clinical benefit (Supplementary Table 5). Seven (63.6%) of these 11 
patients with germline BRCA1/2 mutant ovarian cancer achieved clinical benefit for a 
median duration of response of 24 weeks (range 11.3 – 115.0); 6 of these 7 patients 
were platinum-resistant. Four other patients with advanced ovarian cancer who also 
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achieved clinical be(3)nefit included those with tumors harboring (1) somatic BRCA1, 
TP53 and AR mutations, (2) somatic BRCA2 and TP53 mutations, (3) somatic 
PTEN, KRAS and SMARCA4 mutations, and (4) somatic TP53 mutation. 
 
Patients with advanced CRPC 
Of four patients with advanced CRPC, three had germline BRCA1/2 
mutations, of whom two achieved clinical benefit (Supplementary Table 5). None of 
the 4 patients had received prior platinum-based chemotherapy. 
 
Prior PARP inhibitor or PI3K pathway inhibitor exposed patients 
Thirteen patients had prior exposure to PARP inhibitors, five of whom had 
clinical benefit on this combination study (Supplementary Table 6). One of the 
patients had high grade serous ovarian cancer (HGSOC) with a somatic BRCA2 
mutation, who achieved RECIST PR and GCIG CA-125 response lasting 31 weeks, 
while another patient with platinum-resistant germline BRCA2 mutant HGSOC with 
somatic TP53 mutation and somatic BRCA1 VUS achieved a GCIG CA-125 
response and RECIST SD lasting 56 weeks. Another patient who had previously 
received a PARP inhibitor had platinum-resistant HGSOC harboring a germline 
BRCA2 mutation and achieved a GCIG CA-125 response and RECIST SD on this 
trial lasting 115 weeks. Only one patient had previously received a PI3K pathway 
inhibitor prior to this clinical trial; she was a patient with advanced peritoneal 
mesothelioma who had previously achieved a RECIST PR on a single agent PI3K 
pathway inhibitor prior to eventually progressing. On this clinical trial, she achieved a 
CA-125 response by GCIG criteria and durable RECIST SD lasting 84 weeks before 
progression.  
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Cell-free DNA analysis 
A total of 157 cfDNA samples were serially collected from 41 patients for 
analysis on a targeted NGS panel. Of these patients, at least one mutation was 
detected in baseline cfDNA samples from 38 (93%) patients. Of 39 patients where 
both tumor and cfDNA samples were available for analysis, mutation status at 
baseline was concordant between tumor and cfDNA samples in 34 (87.2%) patients. 
All germline and somatic mutations detected through germline and/or tumor testing 
were detected in cfDNA. The most common mutations detected in cfDNA included 
TP53 (n=26 [63.4%] patients), BRCA2 (n=11 [26.8%]), BRCA1 (n=7 [17.1%]), KRAS 
(n=4 [9.8%]), PIK3CA (n=3 [7.3%]), ARID1A (n=3 [7.3%]) and PTEN (n=2 [4.9%]). 
 
The cfDNA allele frequencies of somatic mutations decreased in selected 
responding patients and increased upon disease progression (Supplementary 
Figures 2A-2F). In patients with known germline mutations, e.g. BRCA1/2 
mutations, falls in the cfDNA allele frequencies of germline mutations toward 50% 
were observed as they responded to trial therapy (Supplementary Figures 2C-2D). 
Of 20 patients harboring germline and/or somatic BRCA1/2 mutations with available 
cfDNA sampling, 5 patients were found to have BRCA1/2 reversion mutations at 
disease progression in their end of treatment cfDNA samples (Supplementary 
Table 7). One of these patients with advanced ovarian cancer, who had early 
disease progression after 4 weeks on trial, had a tumor somatic BRCA1 mutation 
(c.329insA, p.K110fs*4) in archived tissue, but was found to have a secondary 
BRCA1 mutation deletion restoring the original reading frame (c.335_338delATAA) 
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 In this study, we have shown that the novel combination of olaparib and 
capivasertib is well tolerated at biologically effective doses that achieve clinical 
benefit, including durable responses, in patients with a range of treatment-refractory 
cancers, including both germline BRCA1/2 mutated tumors, and sporadic cancers 
harboring actionable somatic alterations. Antitumor responses were also observed in 
patients who had previously developed disease progression on PARP and PI3K 
pathway inhibitors.  
 
Two different intermittent schedules of capivasertib were assessed to 
determine differences in safety, tolerability, PK-PD activity and antitumor responses 
in combination with olaparib, by comparing a high dose of capivasertib given over a 
shorter 2/5 schedule versus a lower dose of capivasertib over a longer 4/3 schedule. 
Overall, this combination was generally well tolerated in both schedules; treatment-
related toxicities were reversible and mainly GI-related, including diarrhea, mucositis, 
nausea and anorexia. Such potential overlapping GI toxicities were effectively 
managed with simple supportive measures when indicated clinically, such as anti-
emetics and anti-diarrheals. No DLTs were observed on the 2/5 schedule, while 1 
DLT of reversible grade 3 rash was observed at the highest tested dose of 480mg 
BID of capivasertib with 300mg BID of olaparib in the 4/3 schedule. Dose 
proportional PKs were observed, and proof-of-mechanism PD studies confirmed 
AKT pathway modulation across dose levels in platelet-rich plasma. Two different 
Research. 
on June 22, 2020. © 2020 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 12, 2020; DOI: 10.1158/2159-8290.CD-20-0163 
 18 
combination RP2Ds were established – 400mg BID of capivasertib with 300mg BID 
of olaparib for the 4/3 schedule, and 640mg BID of capivasertib with 300mg BID of 
olaparib with for the 2/5 schedule.  
 
This study employed a prospective intrapatient dose escalation trial design, 
which enabled the rapid completion of dose escalation phases of two different 
combination schedules, each involving 3 dose levels, within 7 months and only 
requiring a total of 10 patients in each schedule. Apart from optimizing speed and 
minimizing patient numbers, this prospective intrapatient dose escalation has 
benefits over established Phase I escalation strategies including minimization of 
patient numbers receiving subtherapeutic drug doses, and safe optimization of drug 
exposures at an individual level to ensure maximal blockade of critical targets for 
combination strategies.  
 
In preclinical studies, inhibition of the PI3K pathway has been shown to lead 
to upregulation of poly-ADP-ribosylation (PAR) and phosphorylation of H2AX, 
indicating increased DNA damage in cells (12). The accumulation of unrepaired DNA 
double stranded breaks in BRCA-deficient cells in turn make them exquisitely 
sensitive to PARP inhibition, potentially accounting for the synergistic effects seen in 
combined olaparib and capivasertib treatment. Apart from germline BRCA mutant 
breast cancers, preclinical studies have also demonstrated that PI3K inhibition in 
triple negative breast cancer (TNBC) models drives ERK-dependent activation of the 
ETS transcription factor, which suppresses BRCA gene transcription, causing a 
deficiency of HR activity and PARP inhibitor sensitivity (11). Correlative tumor 
studies from this study have shown increases in tumor phosphorylated ERK 
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expression associated with decreases in BRCA1 expression levels, supporting this 
hypothesis and rationale for this novel combination (14). Given that ERK 
phosphorylation may potentially have negative protumor consequences as well, 
future studies should investigate if this may represent a compensatory response that 
blunts antitumor efficacy. 
 
The combination of olaparib and capivasertib on both 4/3 and 2/5 schedules 
have shown evidence of antitumor activity, with clinical benefit observed in 44.6% of 
evaluable patients on study. Fourteen (56%) of these 25 responding patients 
harbored germline BRCA1/2 mutations, while 8 (32%) of 25 had relevant somatic 
aberrations, including BRCA2, PIK3CA, PTEN, and PALB2 mutations (Figure 3A). 
All three patients with tumors harboring both DDR-related and PI3K pathway related 
aberrations had RECIST PRs, eight of 23 evaluable patients with tumors harboring 
only DDR-related tumor mutations achieved RECIST PR, and 1 of 5 patients 
deficient for PTEN had a RECIST PR (Figures 2B-2C). Importantly, clinical benefit 
was also observed in patients with neither PI3K pathway nor DDR-related tumor 
mutations detected, as well as in patients who had previously progressed on PARP 
or PI3K pathway inhibitors. While based on small numbers, these findings are in 
keeping with preclinical studies, which indicate that efficacy is not necessarily 
confined to tumors with actionable mutations such as BRCA1/2 mutations (11,12). 
Regardless, a suitably-powered randomized trial will be necessary to formally 
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In this study, concordance in the detection of selected mutations between 
cfDNA and tumor was 87.2%, supporting the use of cfDNA for the contemporaneous 
molecular profiling of patients. This high concordance may be associated with the 
large proportion of patients with germline mutation cancers included in this trial. 
Similar to previous studies (22), the cfDNA allele frequencies of somatic mutations 
decreased in selected responding patients and increased upon disease progression. 
Falls in the allele frequencies of germline mutations toward 50% were observed as 
they responded to trial therapy, suggesting elimination of the tumor clone (22). The 
development of BRCA1/2 reversion mutations was observed at disease progression 
in cfDNA from five (25%) out of 20 patients with BRCA1/2 mutant cancers with 
available cfDNA for analysis (Supplementary Table 7). This finding supports BRCA 
reversion as a likely resistance mechanism in PARP inhibitor-based therapies, 
including regimens such as this olaparib-capivasertib combination, and advocates 
the use of serial cfDNA sampling longitudinally in detecting the emergence of such 
aberrations. The patient with a BRCA1 reversion mutation detected in cfDNA at 
baseline and again at early disease progression had primary resistance to this 
combination, suggesting that the detection of such aberrations in cfDNA should also 
be considered as part of screening tests prior to PARP inhibitor based therapies 
(22,23).  
 
Five (71.4%) out of 7 patients with germline BRCA1/2 mutant breast cancers 
achieved clinical benefit. In the phase 3 OlympiAD trial where patients with germline 
BRCA1/2 mutant HER2-negative metastatic breast cancer were randomized to 
receive olaparib or single-agent chemotherapy of the physician’s choice, the 
response rate was 59.9% in the olaparib group and 28.8% in the standard-therapy 
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group (6). Although based on small numbers, our study provides preliminary clinical 
data that supports the combination of capivasertib with olaparib as a rational strategy 
to potentially improve patient benefit beyond that of single agent olaparib. The 
addition of capivasertib to first line paclitaxel chemotherapy for TNBC was also 
shown to lead to significantly longer progression-free survival (PFS) and overall 
survival (OS) in a randomized, double-blind, placebo-controlled phase 2 trial, 
particularly in patients with tumors harboring PIK3CA/AKT1/PTEN alterations (24). In 
addition, the FAKTION phase 2 trial showed that the addition of capivasertib to 
fulvestrant in patients with endocrine-resistant, advanced estrogen receptor positive 
breast cancer also resulted in significantly longer PFS and an observed OS 
improvement of approximately 6 months, although this was not statistically significant 
(37% OS data maturity) (25). Phase 3 trials of capivasertib-based combinations are 
planned or ongoing. 
 
We observed clinical benefit in 7 of 10 patients (median duration of response 
for these responders was 24 weeks, range 11.3 – 115.0) with germline BRCA1/2 
mutant ovarian cancer, of which 6 were platinum-resistant. Overall, 6 (24%) of 25 
patients with advanced ovarian cancer achieved RECIST PR, while 5 (20%) had 
RECIST SD. An ongoing Phase Ib/2 trial of olaparib and capivasertib in patients with 
advanced ovarian, endometrial and triple negative breast cancer used the 
combination RP2D established in this trial of 400mg BID of capivasertib with 300mg 
BID of olaparib in the 4/3 schedule. Preliminary results from this trial have shown a 
RECIST PR rate of 7 (24%) of 30 patients, including RECIST PRs in four of 8 
patients with recurrent endometrial cancer, 2 patients with TNBC and 1 patient with 
ovarian cancer, as well as RECIST SD≥ 4 months in 6 additional patients (26). This 
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compares with 10 (36%) of 28 patients with ovarian cancer achieving RECIST PR, 
and 14 (50%) attaining RECIST SD in the phase Ib trial of olaparib in combination 
with the -specific PI3K inhibitor alpelisib (15). 
 
 In summary, capivasertib in combination with olaparib was well tolerated in 
both 4/3 and 2/5 schedules. Blockade of AKT led to a downregulation of pSer9 
pGSK3β, indicating target modulation, while increased pERK and decreased BRCA1 
expression provided translational mechanistic insights into potential synergistic 
activity between capivasertib and olaparib. Antitumor activity was observed more 
frequently in patients with either germline BRCA1/2 mutant cancers and sporadic 
cancers with somatic aberrations along the DDR and PI3K/AKT pathways. There 
were also preliminary signals of clinical benefit in platinum-resistant HGSOC and in 
patients who had received prior PARP inhibitors. Our results support the 
development of the combination of olaparib and capivasertib as a promising strategy 
that warrants further exploration in future clinical trials. 
 
METHODS 
This investigator-initiated study (ClinicalTrials.gov: NCT02338622) was 
designed by TAY and JDB, with support from AstraZeneca, and conducted in 
accordance with the provision of the Declaration of Helsinki and Good Clinical 
Practice guidelines. Dose escalation was conducted at the Royal Marsden NHS 
Foundation Trust (RM), London, UK, while the dose expansion phase also involved 
University College London Hospital, London, Northern Centre for Cancer Care, 
Newcastle, and Cambridge University Hospitals NHS Foundation Trust, Cambridge, 
UK. The Central London Research Ethics Committee (REC) approved the protocol 
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(REC reference 14/LO/0103). The trial was co-sponsored by the Institute of Cancer 
Research (ICR) and RM, and centrally managed by the Drug Development Unit 
(Investigator Initiated Trials Team) at the ICR/RM. Funding was provided by the 
Experimental Cancer Medicine Centres (ECMC) network, National Institute of Health 
Research, Cancer Research UK (CR-UK), and AstraZeneca. 
 
Study population 
Eligible patients had histologically confirmed advanced solid tumors refractory 
to standard therapies and Eastern Cooperative Oncology Group performance status 
(ECOG PS) 0-1. Complete eligibility criteria are available in the Data Supplement. 
Dose expansion cohorts mandated patients with germline BRCA1/2 mutated tumors 
(Cohort A) or germline BRCA1/2 wildtype patients with sporadic tumors likely to 
harbor HR defects or demonstrating somatic aberrations known to result in a 
hyperactivated PI3K-AKT pathway (or defective DNA repair) (Cohort B). The dose 
escalation cohort was enriched for patients with characteristics mandated in 
expansion cohorts A and B, but this was not a requirement. Written informed consent 
was obtained from all patients.  
 
Trial design 
 This was an open-label, multicenter phase Ib trial assessing the combination 
of olaparib and capivasertib in patients with advanced solid tumors. The primary 
objectives were to determine the safety and tolerability of olaparib in combination 
with capivasertib, and to establish a MTD and/or RP2D of this combination. 
Secondary objectives included the characterization of PK and PD profiles of both 
agents in combination. Exploratory objectives included the assessment of 
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preliminary antitumor activity of the combination and evaluation of putative predictive 
biomarkers of response and resistance. Study conduct was overseen by a Safety 
Review Committee (SRC), comprising the Chief Investigator, Principal Investigator or 
delegate from each investigational site, DDU Pharmacovigilance Officer or delegate, 
CR-UK’s Drug Development Office medical advisor or delegate, an observer from 
AstraZeneca, a Clinical Trials Manager or delegate, an independent senior ECMC 
network clinician and a RMH representative who was independent of the study team. 
 
Prospective intrapatient dose escalation 
 This phase I trial utilized a prospective intrapatient dose escalation trial 
design, where doses of capivasertib were prospectively escalated in each patient in 
combination with a fixed continuous dose of olaparib (Supplementary Figure 1; 
Supplementary Methods). 
  
Toxicities and laboratory variables were assessed using the Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.0. Patients had safety 
evaluations weekly and tumor response assessments after every three treatment 
cycles, using computer tomography scans evaluated by RECIST version 1.1. As 
appropriate, different tumor markers were used to assess the effects of study 
treatment on respective tumor types, e.g. serum CA-125 was assessed in patients 
with ovarian cancer according to GCIG criteria or serum PSA levels in patients with 
CRPC according to PCWG2 criteria. 
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Pharmacokinetics and pharmacodynamics 
PK modelling was conducted using a non-compartmental extravascular model 
for plasma with PhoenixTM WinNonLin Software version 64 (Pharsight). PD 
Biomarker analysis of pSer9 GSK3 was undertaken on PRP where available, using 
assays validated to Good Clinical Practice standards on the MesoScale Discovery 
(MSD®) technology platform (Supplementary Methods) (27). ERK expression was 
assessed using immunohistochemistry conducted on formalin-fixed, paraffin-
embedded (FFPE) tissue sections (Supplementary Methods). BRCA1 expression 
was assessed using a BRCA1 pan-nuclear IHC staining (Supplementary Methods).  
 
Predictive biomarker studies 
Targeted next generation sequencing studies were conducted on patients with 
available tumor tissue at the Institute of Cancer Research (Supplementary 
Methods); libraries were constructed with the use of GeneRead DNA seq Panel 
(Qiagen) and run on a MiSeq sequencer (Illumina). Whole exome sequencing was 
also performed on germline and tumor DNA of responding patients using Illumina 
HiSeq 2500 in paired-end mode. Variants are annotated as pathogenic if considered 
‘pathogenic’ or ‘likely pathogenic’ according to the ClinVar database (28) and/or 
ACMG classification using VarSome (29). PTEN loss was assessed by 
immunohistochemistry performed on FFPE tissue sections from archived tumor 
where available as previously described (30). 
 
Statistical analysis 
Analysis was conducted after all patients had received 1 cycle of treatment 
and had completed their last study visit conducted 28 days after the last dose of 
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combination treatment. Patients were evaluable for antitumor efficacy assessment if 
they had at a baseline RECIST assessment and at least one post-baseline RECIST 
assessment. Under the assumption that the true underlying CBR was 20%, with 
anticipated recruitment of 40 patients in the expansion phase, there would be a <1% 
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Table 1: Patient Demographics 
Characteristic 
Olaparib 300mg BID and Capivasertib BID either 4-





Schedule, n=33 (52%) 
2-days-on, 5-days-off 
Schedule, n=31 (48%) 
n=64 (100%) 
Median age, years 
(range) 
59 (32-76) 54 (32-72) 57 (32-76) 
Gender No. (%) 
   
Male 6 (18) 5 (16) 11 (17) 
Female 27 (82) 26 (84) 53 (83) 
ECOG PS, No. (%) 
   
ECOG PS 0 13 (39) 9 (29) 22 (34) 
ECOG PS 1 20 (61) 22 (71) 42 (66) 
Tumor, No. (%) 
   
Ovarian 
13 (39)  
[7 germline BRCA1/2; 4 
somatic BRCA1/2] 
12 (39)  




8 (24)  
[2 germline BRCA1/2] 
10 (32)  
[5 germline BRCA1/2; 1 
germline PALB2] 
18 (28) 
Pancreatic 3 (9) 2 (7) 5 (8) 
CRPC 
2 (6) 
[1 germline BRCA1/2] 
2 (7) 
[2 germline BRCA1/2] 
4 (6) 
Cervical 2 (6) - 2 (3) 
Endometrial 1 (3) 1 (3) 2 (3) 
Bladder 1 (3) - 1 (1.5) 
Colorectal 1 (3) - 1 (1.5) 
Cholangiocarcinoma - 1 (3) 1 (1.5) 
GIST - 1 (3) 1 (1.5) 
Cancer of unknown 
origin (CUP) 
1 (3) - 1 (1.5) 
Pleural mesothelioma - 1 (3) 1 (1.5) 
Peritoneal 
mesothelioma 
- 1 (3) 1 (1.5) 
Carcinosarcoma 
(uterine) 
- 1 (3) 1 (1.5) 
Median prior lines of 
systemic therapy, 3 (1-10) 5 (1-12) 4 (1-12) 
No. (range) 
Ovarian (n=25) 5 (1-9) 5 (4-12) 5 (1-12) 
Breast (n=18) 3 (2-10) 4 (3-9) 3 (2-10) 
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Table 2: Treatment-Related Adverse Events during dose escalation 
Table 2A: Treatment-Related Adverse Events (maximum grade, all cycles) for olaparib 300mg BID and capivasertib  
4-days-on, 3-days-off schedule during dose escalation 
 
Olaparib 300mg BID and 
Capivasertib BID 320mg 
(n=6) 
Olaparib 300mg BID and 
Capivasertib BID 400mg 
(n=7) 
Olaparib 300mg BID and 
Capivasertib BID 480mg 
(n=6) 
Grade 1 or 2 Grade 3 or 4 Grade 1 or 2 Grade 3 or 4 Grade 1 or 2 Grade 3 or 4 
Specific Organ Class Preferred Term n % n % n % n % n % n % 
Blood and lymphatic system 
disorders 
Anemia 0 0.0 0 0.0 1 14.3 1 14.3 2 33.3 1 16.7 
Neutropenia 1 16.7 0 0.0 1 14.3 0 0.0 1 16.7 0 0.0 
Thrombocytopenia 1 16.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
Gastrointestinal disorders Abdominal pain 0 0.0 0 0.0 1 14.3 0 0.0 0 0.0 0 0.0 
Constipation 0 0.0 0 0.0 0 0.0 0 0.0 1 16.7 0 0.0 
Diarrhea 2 33.3 0 0.0 0 0.0 0 0.0 1 16.7 2 33.3 
Melena 0 0.0 0 0.0 1 14.3 0 0.0 0 0.0 0 0.0 
Mouth ulceration 0 0.0 0 0.0 1 14.3 0 0.0 0 0.0 0 0.0 
Nausea 5 83.3 0 0.0 1 14.3 0 0.0 5 83.3 0 0.0 
Vomiting 1 16.7 0 0.0 3 42.9 0 0.0 1 16.7 1 16.7 
General disorders and 
administration site conditions 
Fatigue 4 66.7 0 0.0 2 28.6 0 0.0 4 66.7 0 0.0 
Mucosal inflammation 2 33.3 0 0.0 2 28.6 0 0.0 1 16.7 0 0.0 
Musculoskeletal and 
connective tissue disorders Myalgia 0 0.0 0 0.0 0 0.0 0 0.0 1 16.7 0 0.0 
Nervous system disorders Dizziness 1 16.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
Dysgeusia 1 16.7 0 0.0 1 16.7 0 0.0 0 0.0 0 0.0 
Renal and urinary disorders Hematuria 0 0.0 0 0.0 1 14.3 0 0.0 0 0.0 0 0.0 
Skin and subcutaneous 
tissue disorders 
Dry skin 0 0.0 0 0.0 0 0.0 0 0.0 1 16.7 0 0.0 
Eczema 0 0.0 0 0.0 0 0.0 0 0.0 1 16.7 0 0.0 
Pruritus 1 16.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
Rash 0 0.0 0 0.0 0 0.0 0 0.0 1 16.7 0 0.0 
Rash maculo-papular 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 16.7 
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Table 2B: Treatment-Related Adverse Events (maximum grade, all cycles) for olaparib 300mg BID and capivasertib BID 2-
days-on, 5-days-off schedule during dose escalation 
 
 
Olaparib 300mg BID and 
Capivasertib BID 480mg 
(n=8) 
Olaparib 300mg BID and 
Capivasertib BID 560mg (n=6) 
Olaparib 300mg BID and 
Capivasertib BID 640mg 
(n=6) 
Grade 1 or 2 Grade 3 or 4 Grade 1 or 2 Grade 3 or 4 Grade 1 or 2 Grade 3 or 4 
Specific Organ Class Preferred Term n % n % n % n % n % n % 
Blood and lymphatic system 
disorders 
Anemia 0 0.0 0 0.0 2 33.3 0 0.0 3 50.0 0 0.0 
Neutropenia 0 0.0 0 0.0 1 16.7 0 0.0 0 0.0 0 0.0 
Gastrointestinal disorders 
Abdominal distension 0 0.0 0 0.0 0 0.0 0 0.0 1 16.7 0 0.0 
Abdominal pain 0 0.0 0 0.0 0 0.0 0 0.0 1 16.7 0 0.0 
Diarrhea 5 62.5 0 0.0 1 16.7 0 0.0 3 50.0 0 0.0 
Gastro-esophageal reflux disease 0 0.0 0 0.0 0 0.0 0 0.0 1 16.7 0 0.0 
Nausea 6 75.0 0 0.0 1 16.7 0 0.0 1 16.7 0 0.0 
Vomiting 1 12.5 0 0.0 2 33.3 0 0.0 2 33.3 0 0.0 
General disorders and 
administration site conditions 
Fatigue 4 50.0 0 0.0 2 33.3 1 16.7 3 50.0 0 0.0 
Mucosal inflammation 0 0.0 0 0.0 1 16.7 0 0.0 1 16.7 0 0.0 
Infections and infestations Oral candidiasis 0 0.0 0 0.0 0 0.0 0 0.0 1 16.7 0 0.0 
Investigations Transaminases increased 0 0.0 1 12.5 0 0.0 0 0.0 0 0.0 0 0.0 
Metabolism and nutrition 
disorders 
Decreased appetite 1 12.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
Hyperglycemia 0 0.0 1 12.5 0 0.0 0 0.0 1 16.7 0 0.0 
Hypokalemia 1 12.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
Nervous system disorders Dysgeusia 0 0.0 0 0.0 0 0.0 0 0.0 1 16.7 0 0.0 
Renal and urinary disorders Glycosuria 1 12.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
Respiratory, thoracic and 
mediastinal disorders 
Cough 0 0.0 0 0.0 0 0.0 0 0.0 1 16.7 0 0.0 
Dyspnea 0 0.0 0 0.0 0 0.0 0 0.0 1 16.7 0 0.0 
Wheezing 0 0.0 0 0.0 0 0.0 0 0.0 1 16.7 0 0.0 
Skin and subcutaneous 
tissue disorders 
Nail ridging 1 12.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
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Table 3: Characteristics of patients who achieved clinical benefit (RECIST CR/PR or SD≥4 months) 
 
Responder 










































1 Breast BRCA2 
BRCA2, 
PIK3CA 






2 Breast None detected 
ERBB2, 
PIK3CA 






3 Breast BRCA1 
BRCA1, 
TP53 
















5 Breast BRCA1 
BRCA1, 
TP53 








7 Breast BRCA1 
BRCA1, 
TP53 




8 Breast None detected 
None 
detected  
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13 Ovarian BRCA1 
BRCA1, 
TP53 
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Responder 










































14 Ovarian BRCA1 
BRCA1, 
TP53 






































18 Ovarian None detected 
BRCA1, 
AR, TP53 















20 Ovarian BRCA2 
BRCA2, 
NF1, TP53 











































24 Prostate BRCA2 
BRCA2, 
CDKN1B 






25 Prostate BRCA2 
BRCA2, 
TP53 
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TABLE LEGENDS 
Table 1: Patient Demographics 
Table 2: Treatment-Related Adverse Events during dose escalation 
Table 3: Characteristics of patients who achieved clinical benefit. 
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FIGURES 
Figure 1: Dose proportionality of Capivasertib during intra-patient dose 
escalation in both the 4-days-on, 3-days-off (Figure 1A) and 2-days-on, 5-days-
off (Figure 1B) schedules.  
PK modelling was conducted using a non-compartmental extravascular model for 
plasma using PhoenixTM WinNonLin Software version 64 (Pharsight). Once the PK 
parameters were established for each patient, the mean AUC to the last sampled 
time point at 12 hours were plotted against the capivasertib dose administered.  
 
Figure 2A: Pharmacodynamic profile of capivasertib and olaparib in serially 
collected PRP during intra-patient dose escalation on a 4 days on 3 days off 
schedule.  
Platelet rich plasma was collected from patients at baseline and pre-dose on day 4 
(4/7) at each escalating dose. The platelet rich plasma was analyzed for the 
expression of AKT proximal substrate pSer9 GSK3 and total GSK3. Points 
represent the levels of pSer9 GSK3 as a percent of the baseline levels normalized 
to the levels of total GSK3 for individual patients and orange lines represent mean 
of all patients at that time point. **p<0.01; ***p<0.001 Paired t-test compared to 
baseline. 
 
Figure 2B: Pharmacodynamic profile of capivasertib and olaparib in serially 
collected PRP during dose expansion on a 2 days on 5 days off schedule.  
During the cohort expansion, to enable PD studies on the 2-days-on, 5-days-off 
schedule, olaparib was administered alone from cycle 0 days -10 to -7, before 
capivasertib was given alone from cycle 0 days -6 to -3, before both drugs were 
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given in combination from cycle 1 day 1. PRP was collected from patients at baseline 
(cycle 0 Day -10), cycle 0 day -5 (post capivasertib only) and cycle 1 day 2 (post 
capivasertib and olaparib combination). PRP was analyzed for the expression of 
AKT proximal substrate pSer9 GSK3 and total GSK3. Points represent the levels 
of pSer9 GSK3 as a percent of the baseline levels normalized to the levels of total 
GSK3 for individual patients and orange lines represent mean of all patients at that 
time point. ***p<0.001, one-way ANOVA. 
 
Figure 2C-2D: Pharmacodynamic effects of capivasertib and olaparib in paired 
tumor biopsies during dose expansion on 640mg BID of capivasertib 2-days-
on, 5-days-off and 300mg BID of olaparib.  
Tumor biopsies were collected from patients at baseline (Pre) and C1D16 (Post). 
Tumor biopsies were analyzed for the expression of phosphorylated ERK (Figure 
1C) and BRCA1 by IHC (Figure 1D). 
 
Figure 3: Antitumor response waterfall and swimmer plots with corresponding 
patient/tumor characteristics.  
Figure 3A. Waterfall plot showing best target lesion response by RECIST 1.1 for 
patients where this could be evaluated. Red bars represent patients harboring 
gerrmline BRCA1/2 mutations, blue bars represent patients with somatic BRCA1/2 
mutations, and grey bars indicate patients who did not have any BRCA1/2 mutations 
detected. Co-occuring genomic alterations are listed above the respective bars in 
responding patients without BRCA1/2 mutations detected. Hatched bars indicate 
patients with a tumor marker response (PSA or CA-125) where these data were 
available.  
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Figure 3B. Waterfall plot showing best target lesion response by RECIST 1.1 for 
patients where this could be evaluated. Mutations used to classify tumors into DDR- 
or PI3K- mutated, or both, are shown below the bars for each patient, along with 
abbreviated site of the primary tumor. Hatched bars indicate patients with a tumor 
marker response (PSA or CA-125) where these data were available. Horizontal 
dotted lines represent RECIST 1.1 thresholds for progression (+20%) and partial 
response (–30%). Genes with mutations are shown with colored tiles. Tumor + 
Plasma denotes mutations observed in all samples, i.e. original Tumor and plasma 
where this was available. Tumor (only) denotes mutation only observed in original 
tumor sample and absent from subsequent plasma samples. Plasma (only) denotes 
a mutation observed only in plasma samples and not the original tumor sample. 
Germline and reversion mutations, as well as PTEN IHC classifications, are shown 
by symbols as indicated. The middle panel shows genes used to classify the tumors 
in the waterfall plot, and the lower panel shows other genes of interest. 
 
Figure 3C. Swimmer plot showing time on study for patients, categorized as in 
Figure 3B. 
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